Natural Versus HRT Cycles in Frozen Embryo Replacement Treatment

Infertility Clinical Trial

Official title:

A Randomised Controlled Trial of Natural Versus Hormone Replacement Therapy Cycles in Frozen Embryo Replacement IVF: a Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00843570
• Other study ID #: FER01
• Secondary ID: EudraCT 2009-009
• Status: Completed
• Phase: Phase 4
• First received: February 12, 2009
• Last updated: July 24, 2013
• Start date: November 2009
• Est. completion date: May 2013

Study information

• Verified date: July 2013
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory AgencyUnited Kingdom: Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

Frozen Embryo Replacement (FER)is a fertility treatment by which stored embryos from a fresh IVF treatment cycle are thawed and transferred into the uterus. Frozen embryos can be replaced either in the middle of a natural menstrual cycle (Natural FER) or in a cycle where the woman takes drugs to suppress her own hormones, and then takes Hormone Replacement Therapy (HRT) to prepare her uterus for the transfer of embryos(HRT − FER).

Both are widely used methods of fertility treatment. However, to date no well designed studies have been reported in which the two methods have been compared. This study aims to compare the two treatments in order to establish the best treatment protocol.

The study design is a single centre open randomized controlled trial funded by the Oxford Fertility Unit.

100 women who are considering FER treatment at the Oxford Fertility Unit and are eligible for the study will be recruited.

After giving their written consent they will be randomised to one of 2 groups: Natural FER and HRT FER.

Patients in both groups will be asked to attend one initial visit, which is additional to patients not taking part in the study.

Subsequent visits will depend on the treatment group but will not be additional for study participants. All visits requiring ultrasound will involve recording 3−D measurements, which increases the length of each visit by approximately 10 minutes. A patient satisfaction questionnaire would be completed at the end of the cycle.

A urinary pregnancy test is performed at home 2 weeks following the embryo transfer visit. If this is positive then further visits to the unit are arranged to confirm the clinical pregnancy.

Inclusion in the study would not increase the length of time of either treatment cycle. Follow up would extend to obtaining pregnancy outcome information.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 159
• Est. completion date: May 2013
• Est. primary completion date: May 2013
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Women attending Oxford Fertility Unit planning a frozen embryo replacement cycle.

• Willing and able to give informed consent for participation in the study.

• Age at original fresh IVF cycle < 40 years old.

• At least 3 embryos frozen in storage

• First or second FER cycle

• Regular ovulatory menstrual cycles, confirmed by luteal progesterone levels >16nmol/L and with cycle length < 35 days.

Exclusion Criteria:

• Women with irregular cycles (outlined above), including amenorrhoea or oligomenorrhoea.

• Co-existing medical illness including renal, cardiac and liver disease

• Women for whom the study medication(s) are contraindicated or who have known allergic reactions to study medication(s)

• Women who have already taken part in this trial (i.e. cannot have more than one treatment cycle as a participant in this trial)

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Infertility

Intervention

Drug:
• Nafarelin acetate, Oestradiol Valerate, Progesterone
Nafarelin acetate, Nasal spray, 400 mcg b.d., 4 weeks Oestradiol Valerate, tablet, 2mg o.d day 1-5, 2mg b.d. day 6-9, 2mg t.d.s day 10-13 (step-up protocol), 2mg q.d.s (if pregnancy confirmed, 4-10 weeks Progesterone, pessary, 200mg b.d. and t.d.s. (if pregnancy confirmed), 2-10 weeks

Locations

Country	Name	City	State
United Kingdom	Nuffield Department of Obstetrics and Gynaecology, University of Oxford	Oxford	Oxfordshire
United Kingdom	Oxford Fertility Unit	Oxford	Oxfordshire

Sponsors (2)

Lead Sponsor	Collaborator
University of Oxford	Oxford Fertility Unit

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The live birth rate in each group		22 - 40 weeks following embryo transfer	No
Secondary	Clinical pregnancy rates (CPR)		4 weeks after embryo transfer (at 6/40 pregnancy)	No
Secondary	Implantation rate (defined as the number gestational sacs visible on ultrasound divided by the number of embryos replaced and expressed in percentage)		4 weeks following embryo transfer (6/40 pregnancy)	No
Secondary	3D endometrial volume and blood flow indices		various from day 1 to embryo transfer	No
Secondary	Patient satisfaction with treatment		4-10 weeks (at embryo transfer)	No